Formulation

An analysis of the approaches and tools used to tackle the problem of poorly soluble drugs.

As technology advances, industry's needs are growing.

Scientists and practitioners must work together for the overall good of the patient.

The authors describe the development of an inclusion complex of GLZ and formulated an extended-release dosage form based on osmotic technology.

Remaining calm, cool, and collected during mergers and inspections is a feat in itself.

The authors discuss gamma scintigraphy as a technique for in vivo evaluation of drugs and delivery systems.

The authors demonstrated that ODTs can be obtained by direct compression of a mixture of starch, fructose, and SMCC.

The authors present an update to the Wyeth/BASF experience with the IPEC Novel Excipient Safety Evaluation Procedure.

Microbubbles can temporarily open many biological barriers for polar molecules, macromolecules, and particles. Scientists have brought well-known contrast agents back to the laboratory and redesigned them as drug carriers. This article is part of a special Drug Delivery issue.

A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.

The author outlines how to choose carriers and capsule shells according to dosage requirements and intended use. This article is part of a special Drug Delivery issue.

PPD and Bend Research Form Collaboration; Ricerca Makes Senior Appointment; And More.

Pfizer Forms Pact with Biocon; Baxter Makes Appointments; And More.

sanofi to Cut 25% of US Workforce; AMRI Names VP of Chemical Development; And More.

On Tuesday, Pfizer (New York) and King Pharmaceuticals (Bristol, TN), a specialty pharmaceutical-discovery and clinical-development company, entered into a definitive merger agreement under which Pfizer will acquire King for $3.6 billion in cash, or $14.25 per share.

Company and People Notes: Novartis Settles with US Attorney's Office; Hospira Names VP, And More.

The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.

The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.

From disagreement to denial, being cordial about quality control can be challenging.

In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.

The authors developed a formulation for effervescent gastroretentive drug delivery techniques using ibuprofen as a model drug. They optimized the formulations by applying full factorial design.

The authors review and discuss the influence of glycans on the conformation of a representative IgG1 biopharmceutical using H/DX-MS as an analytical tool.

Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.

DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.

Genzyme Sells Genetics Business; Bausch and Lomb Names Vice-President; and More.

Pfizer to Acquire FoldRx; Protalix Appoints COO; And More.

Company and People Notes: Lonza Acquired Vivante; PPD Appoints VP of Quality Management; And More.

Pending legislation may give FTC the authority to regulate all Hatch-Waxman settlements.

Industry participation is crucial as USP embarks on far-reaching monograph modernization initiative. This is an online-exclusive article.

New data provide insight into pharma-industry professionals' daily lives.